Harbour BioMed and Bristol Myers Squibb Forge Strategic Partnership for Advanced Antibody Development
In a significant move within the biopharmaceutical sector, Harbour BioMed, publicly traded on HKEX with the ticker 02142, has announced a strategic collaboration with Bristol Myers Squibb (BMS). The focus of this partnership is to discover and develop next-generation multi-specific antibodies, a field burgeoning with potential in immunology and oncology. The agreement outlines mutual cooperation for the upcoming years, aiming to expedite the progression of antibody discovery programs.
According to the terms of the deal, Harbour BioMed stands to gain payments amounting to $90 million, in addition to an impressive $1.035 billion in potential development and commercialization milestones. This figure could increase further with tiered royalties if BMS decides to advance all targeted programs through to clinical trials and beyond.
Dr. Jingsong Wang, the Founder, Chairman, and CEO of Harbour BioMed, expressed enthusiasm about the partnership. He stated, "We are delighted to collaborate with Bristol Myers Squibb to advance next-generation multi-specific antibody discovery and development." This partnership uniquely leverages the Harbour Mice® technology platform, renowned for its efficiency in producing fully human antibodies that have the potential to revolutionize therapies for various diseases.
The Harbour Mice® platform enables the development of monoclonal antibodies in dual heavy and light chain formats, presenting a strategic advantage for Harbour BioMed in catering to the ever-evolving demands of antibody therapeutics. Notably, their HCAb-based immune cell engagers (HBICE®) technology is pioneering, designed to deliver tumor-killing effects that traditional therapies may not achieve. This innovative approach places Harbour BioMed in a favorable position to lead in novel therapeutic advancements.
With an operational base that extends globally, including significant clinical development prospects in China, Harbour BioMed is well-positioned to initiate early-stage clinical trials in cooperation with Bristol Myers Squibb. This geographic advantage allows them to expedite the development timeline, being in close proximity to one of the world's largest patient populations, providing critical insights and faster feedback during the clinical development phases.
The partnership is set against a backdrop of a rapidly evolving market for innovative biopharmaceuticals. The continuous development of antibody therapies offers expansive potential for treating various types of cancers and autoimmune diseases, aiming at not just symptom management but potential cures.
As this collaboration unfolds, both companies expect to tightly integrate their respective strengths, propelling forward in the competitive field of biotherapeutics. Harbour BioMed's established R&D framework and Bristol Myers Squibb's legacy in drug discovery promise a formidable alliance aimed at addressing significant healthcare challenges.
In summary, this collaboration not only signifies a milestone for Harbour BioMed in their ambitious roadmap but also reflects the growing trend in the biopharmaceutical industry where partnerships amplify the capabilities of each entity involved. Through this strategic collaboration, it is likely that we will witness advancements that could greatly benefit patients worldwide, showcasing the synergistic power of combining innovation with expertise in drug development.
According to the terms of the deal, Harbour BioMed stands to gain payments amounting to $90 million, in addition to an impressive $1.035 billion in potential development and commercialization milestones. This figure could increase further with tiered royalties if BMS decides to advance all targeted programs through to clinical trials and beyond.
Dr. Jingsong Wang, the Founder, Chairman, and CEO of Harbour BioMed, expressed enthusiasm about the partnership. He stated, "We are delighted to collaborate with Bristol Myers Squibb to advance next-generation multi-specific antibody discovery and development." This partnership uniquely leverages the Harbour Mice® technology platform, renowned for its efficiency in producing fully human antibodies that have the potential to revolutionize therapies for various diseases.
The Harbour Mice® platform enables the development of monoclonal antibodies in dual heavy and light chain formats, presenting a strategic advantage for Harbour BioMed in catering to the ever-evolving demands of antibody therapeutics. Notably, their HCAb-based immune cell engagers (HBICE®) technology is pioneering, designed to deliver tumor-killing effects that traditional therapies may not achieve. This innovative approach places Harbour BioMed in a favorable position to lead in novel therapeutic advancements.
With an operational base that extends globally, including significant clinical development prospects in China, Harbour BioMed is well-positioned to initiate early-stage clinical trials in cooperation with Bristol Myers Squibb. This geographic advantage allows them to expedite the development timeline, being in close proximity to one of the world's largest patient populations, providing critical insights and faster feedback during the clinical development phases.
The partnership is set against a backdrop of a rapidly evolving market for innovative biopharmaceuticals. The continuous development of antibody therapies offers expansive potential for treating various types of cancers and autoimmune diseases, aiming at not just symptom management but potential cures.
As this collaboration unfolds, both companies expect to tightly integrate their respective strengths, propelling forward in the competitive field of biotherapeutics. Harbour BioMed's established R&D framework and Bristol Myers Squibb's legacy in drug discovery promise a formidable alliance aimed at addressing significant healthcare challenges.
In summary, this collaboration not only signifies a milestone for Harbour BioMed in their ambitious roadmap but also reflects the growing trend in the biopharmaceutical industry where partnerships amplify the capabilities of each entity involved. Through this strategic collaboration, it is likely that we will witness advancements that could greatly benefit patients worldwide, showcasing the synergistic power of combining innovation with expertise in drug development.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.